AroCell has announcd the publication of a study in the European Urology Open Science journal.
The post New study about Arocell’s sTK1 published appeared first on NLS.
Takara Bio Europe has announced the expansion of its Gothenburg facility with the addition of a custom manufacturing lab, which came into operation on October 1st.
The post Takara Bio Europe expands its Gothenburg site appeared first on NLS.
The EU legislation for substances of human origin (SoHOs) has been revised, bringing blood products, tissues and cells under one regulation.
The post Understanding the impact of the EU’s updated SoHO legislation on ATMPs appeared first on NLS.
In a financial market that’s still catching its breath after the repeated turmoil of the past few years, many up-and-coming life science companies in the Nordics are struggling to secure investments and bring their product to market.
The post Do’s and don’ts for young companies on their journey to market appeared first on NLS.
With the formation of WiLD Norway, Norway becomes the third of the five Nordic countries to launch an organization dedicated to empowering women in life science. Following the footsteps of Women in Life Science Denmark (WILD) and VILDA in Sweden, something big is brewing across the region, drawing global attention from the life science industry. But why here, and why now? To find out, Nordic Life Science Magazine headed to Oslo to speak with the team behind WiLD Norway.
The post Momentum Building for Women in Life Science Across the Nordics appeared first on NLS.
Projects receiving grants from Knut and Alice Wallenberg Foundation includes new, effective, personal cancer immunotherapy and improved protection against infections and viruses.
The post SEK 835 million granted to 30 Swedish research projects appeared first on NLS.
Researchers have discovered a variant of the bacteria that causes stomach cancer.
The post Newly discovered stomach bacteria can help in cancer research appeared first on NLS.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending approval of Alhemo (concizumab) as the first once-daily subcutaneous prophylactic treatment for people aged 12 years or older living with haemophilia A or B with inhibitors.
The post Novo Nordisk’s Alhemo recommended for European approval appeared first on NLS.
BioArctic's partner Eisai has announced that the Therapeutic Goods Administration (TGA) of Australia issued a public statement about the initial decision not to register the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab for the treatment of patients with mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia.
The post Eisai will request reconsideration of initial decision for lecanemab in Australia appeared first on NLS.
Through this investment of 12,500 square meters distributed on four levels, the conditions for continued expansion in the coming years are strengthened.
The post New laboratory building inaugurated at Medicon Village appeared first on NLS.